Joshua Bomsztyk, Sriram Ravichandran, Hannah Victoria Giles, Nicola Jane Wright, Oscar Berlanga, Jahanzaib Khwaja, Shameem Mahmood, Brendan Wisniowski, Oliver C Cohen, Darren Foard, Janet Gilbertson, Muhammad Umaid Rauf, Neasa Starr, Ana Martinez-Naharro, Lucia Venneri, Carol Whelan, Marianna Fontana, Philip N Hawkins, Julian D Gillmore, Helen J Lachmann, Stephen Harding, Guy Pratt, Ashutosh D Wechalekar
Amyloidogenic serum free light chains (sFLC) drive disease progression in AL amyloidosis. Matrix-assisted laser desorption/ionization-time of flight mass spectrometry-based free light chain assay (FLC-MS) has greater sensitivity than conventional sFLC assays allowing for the detection of serological residual disease. We report the utility of FLC-MS in a large series of patients with AL amyloidosis assessing the impact of FLC-MS negativity after treatment on overall survival and organ response rates. Serum samples were analysed using FLC-MS at diagnosis and at 6-, and 12months post-treatment...
January 9, 2024: Blood